COVID-19 Vaccines and the Viral Variants: New Aspects of Vaccine Research

Presenters

Mark J. Mulligan, MD
New York University

Start

June 29, 2021 - 10:00 AM

End

June 29, 2021 - 11:15 AM

Add to iCal Calendar

Overview

Assessment of Needs

This state-of-the-art activity as part of a nationwide continuing education effort for physicians on the evolving challenges of managing relevant viral infections and concominant diseases and comorbidities. This webinar will provide the latest data regarding COVID-19 vaccines, vaccine development process, and clinical trials, including the latest emerging issues and the likely next phases of the pandemic.

Learning Objectives

On completion of this webinar, learners will be able to:

  • Describe recent data from COVID-19 vaccine clinical trials
  • Identify emerging issues regarding COVID-19

Registration

Who Should Attend

This  webinar is designed for clinical decision makers who are interested in the current state of COVID-19 pandemic.

This activity is also relevant for nursing professionals, physician assistants, pharmacists, and other health care professionals.

Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.

Registration closes on Tuesday, June 29, 2021, 9:00 AM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Presenter Disclosure

Dr Mulligan has received consulting or advisor fees from Meissa Vaccines, Inc. and research grants/grants pending from Eli Lilly and Company and Pfizer. (Updated 04/05/2021)

All relevant financial relationships have been mitigated.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Points

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Credits

These activities are eligible for ANCC credit, see final CNE activity announcement for specific details.

Pharmacy Credits

Accreditation Council for Pharmacy Education logoAccreditation Council for Pharmacy Education logoThese activities are eligible for ACPE credit, see final CPE activity announcement for specific details.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

PLATINUM SUPPORTERS

Gilead Sciences, Inc.
Merck & Co., Inc.
ViiV Healthcare

SILVER SUPPORTER

Janssen Therapeutics

BRONZE SUPPORTER

Theratechnologies Inc.

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.